HLB bioStep Co.,Ltd. (KOSDAQ:278650)

Patterson Companies Statistics

Total Valuation

HLB bioStep has a market cap or net worth of KRW 109.56 billion. The enterprise value is 106.91 billion.

Market Cap	109.56B
Enterprise Value	106.91B

Important Dates

The next estimated earnings date is Thursday, August 14, 2025.

Earnings Date	Aug 14, 2025
Ex-Dividend Date	n/a

Share Statistics

HLB bioStep has 84.47 million shares outstanding. The number of shares has increased by 6.14% in one year.

Current Share Class	84.47M
Shares Outstanding	84.47M
Shares Change (YoY)	+6.14%
Shares Change (QoQ)	-6.50%
Owned by Insiders (%)	4.96%
Owned by Institutions (%)	4.60%
Float	66.03M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.82
PB Ratio	0.95
P/TBV Ratio	1.08
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-13.26
EV / Sales	1.78
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-11.58

Financial Position

The company has a current ratio of 2.71, with a Debt / Equity ratio of 0.26.

Current Ratio	2.71
Quick Ratio	2.39
Debt / Equity	0.26
Debt / EBITDA	n/a
Debt / FCF	-3.23
Interest Coverage	-14.12

Financial Efficiency

Return on equity (ROE) is -7.69% and return on invested capital (ROIC) is -5.39%.

Return on Equity (ROE)	-7.69%
Return on Assets (ROA)	-5.03%
Return on Invested Capital (ROIC)	-5.39%
Return on Capital Employed (ROCE)	-9.47%
Revenue Per Employee	401.20M
Profits Per Employee	-53.77M
Employee Count	150
Asset Turnover	0.37
Inventory Turnover	11.11

Taxes

Income Tax	-2.61B
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -44.24% in the last 52 weeks. The beta is 0.16, so HLB bioStep's price volatility has been lower than the market average.

Beta (5Y)	0.16
52-Week Price Change	-44.24%
50-Day Moving Average	1,487.02
200-Day Moving Average	1,894.68
Relative Strength Index (RSI)	24.46
Average Volume (20 Days)	155,085

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, HLB bioStep had revenue of KRW 60.18 billion and -8.07 billion in losses. Loss per share was -95.37.

Revenue	60.18B
Gross Profit	42.66B
Operating Income	-13.23B
Pretax Income	-12.01B
Net Income	-8.07B
EBITDA	-8.32B
EBIT	-13.23B
Loss Per Share	-95.37

Balance Sheet

The company has 37.23 billion in cash and 29.85 billion in debt, giving a net cash position of 7.38 billion or 87.34 per share.

Cash & Cash Equivalents	37.23B
Total Debt	29.85B
Net Cash	7.38B
Net Cash Per Share	87.34
Equity (Book Value)	115.77B
Book Value Per Share	1,314.46
Working Capital	32.23B

Cash Flow

In the last 12 months, operating cash flow was -7.91 billion and capital expenditures -1.32 billion, giving a free cash flow of -9.23 billion.

Operating Cash Flow	-7.91B
Capital Expenditures	-1.32B
Free Cash Flow	-9.23B
FCF Per Share	-109.28

Margins

Gross margin is 70.90%, with operating and profit margins of -21.99% and -13.40%.

Gross Margin	70.90%
Operating Margin	-21.99%
Pretax Margin	-19.95%
Profit Margin	-13.40%
EBITDA Margin	-13.82%
EBIT Margin	-21.99%
FCF Margin	n/a

Dividends & Yields

HLB bioStep does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-6.14%
Shareholder Yield	n/a
Earnings Yield	-7.36%
FCF Yield	-8.43%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on May 31, 2022. It was a forward split with a ratio of 9.

Last Split Date	May 31, 2022
Split Type	Forward
Split Ratio	9

Scores

HLB bioStep has an Altman Z-Score of 3.51 and a Piotroski F-Score of 4.

Altman Z-Score	3.51
Piotroski F-Score	4